GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...
UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...
Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...
Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Altruist Biologics, the Contract Development and Manufacturing Organization (CDMO) unit of China-based Innovent Biologics, Inc. (HKG:...
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
The Center for Drug Evaluation (CDE) in China has indicated on its website that the...
Alma Lasers, a subsidiary of Sisram Medical (HKG: 1696), has announced the commercial availability of...
The Center for Drug Evaluation (CDE) website indicates that UK pharmaceutical major AstraZeneca’s (AZ, NASDAQ:...
Kanova Biopharma, a Suzhou-based developer of antibodies focused on autoimmune diseases and oncology, has reportedly...
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...
Taiwan-based HanchorBio has announced that it has received approval from the Taiwan Food and Drug...
Japan-based Sosei Group Corporation (TYO: 4565) has announced that its subsidiary, Sosei Heptares, has acquired...
Beijing InnoCare Pharma (HKG: 9969), a China-based biotech company specializing in cancer and autoimmune diseases,...
Germany-based Boehringer Ingelheim and its US partner Eli Lilly & Co., (NYSE: LLY), have reported...
US-based biopharmaceutical company Biogen (NASDAQ: BIIB) has released its financial report for the second quarter...
The US Food and Drug Administration (FDA) has granted clearance to Japan-based Daiichi Sankyo (TYO:...
Gilead Sciences (NASDAQ: GILD) has decided to stop pursuing the potential first-in-class immunotherapy, magrolimab, for...
The European Union (EU) has announced a EUR 3 million (USD 3.3 million) funding injection...